Crossmark

Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Crossref DOI link: https://doi.org/10.1186/s40360-020-0382-y

Published Online: 2020-01-06

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pitchford, Lisa M. http://orcid.org/0000-0002-6402-0823
Driver, Patricia M.

Fuller, John C. Jr

Akers, Wendell S.

Abumrad, Naji N.

Amarnath, Venkataraman

Milne, Ginger L.

Chen, Sheau-Chiann

Ye, Fei

Roberts, L. Jackson II

Shoemaker, M. Benjamin

Oates, John A.

Rathmacher, John A.

Boutaud, Olivier
Funding

Funding for this research was provided by:

National Institute on Aging (AG055184)

National Center for Advancing Translational Sciences (TR000445, UL1TR002243)

American Heart Association (18SFRN34110369)
License Information

Text and Data Mining valid from 2020-01-06

Version of Record valid from 2020-01-06
More Information

Article History

Received: 26 August 2019

Accepted: 31 December 2019

First Online: 6 January 2020

Ethics approval and consent to participate

: The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.

: Not applicable.

: JCF, LMP, and JAR are employed by and NNA is co-founder and part owner of MTI BioTech Inc., which has executed an agreement for the rights to license the intellectual property for 2-hydroxybenzylamine from Vanderbilt University. WSA received payment for the clinical pharmacokinetic analysis.

Document is current

Any future updates will be listed below